HONG KONG SAR - Media OutReach Newswire - 27 March 2025 - At today's press conference, members of the education expert panel on vitiligo, including Dr Johnny Chan Chun-yin, ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

Intrinsic alterations in the skin of patients with vitiligo include a thicker epidermis with a reduced number of basal melanocytes and the presence of degenerated keratinocytes with swollen ...

Results in vitiligo came from the TRuE-V1 and TRuE-V2 studies, which showed that around 30% of patients treated with ruxolitinib cream twice daily achieved 75% or more improvement from baseline in ...

Vitiligo appears as patches of skin that have ... The patches may take some months to return to their former color, and sun cream should be used to protect the skin from the sun.

Research into vitiligo could lead to new treatment options within the next few years, a dermatologist involved in the study has said. Viktoria Eleftheriadou has studied the disease since 2009 ...

Significantly more patients who applied ruxolitinib cream 1.5% versus vehicle control ... compared to its use for atopic dermatitis and vitiligo. Price Action: INCY stock is up 0.92% at $71. ...